Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 326.8 g/mol |
---|---|
Molecular Formula | C18H19ClN4 |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 1 |
Exact Mass | 326.1298243 g/mol |
Monoisotopic Mass | 326.1298243 g/mol |
Topological Polar Surface Area | 30.9 A^2 |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 584 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Clozapine |
PubMed Health | Clozapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | VERSACLOZ, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.The structural formula is: VERSACLOZ is available as a free-flowing yellow suspension. Each mL c... |
Active Ingredient | Clozapine |
Dosage Form | Tablet |
Route | Oral |
Strength | 200mg; 100mg; 25mg; 50mg; 12.5mg |
Market Status | Prescription |
Company | Ivax Sub Teva Pharms; Sun Pharm Inds; Mylan |
2 of 6 | |
---|---|
Drug Name | Clozaril |
PubMed Health | Clozapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | CLOZARIL (clozapine), an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine.The structural formula isCLOZARIL is available in pale yellow tablets of 25mg... |
Active Ingredient | Clozapine |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 25mg |
Market Status | Prescription |
Company | Novartis |
3 of 6 | |
---|---|
Drug Name | Fazaclo odt |
Active Ingredient | Clozapine |
Dosage Form | Tablet, orally disintegrating |
Route | Oral |
Strength | 200mg; 100mg; 25mg; 150mg; 12.5mg |
Market Status | Prescription |
Company | Jazz Pharms Iii |
4 of 6 | |
---|---|
Drug Name | Clozapine |
PubMed Health | Clozapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | VERSACLOZ, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.The structural formula is: VERSACLOZ is available as a free-flowing yellow suspension. Each mL c... |
Active Ingredient | Clozapine |
Dosage Form | Tablet |
Route | Oral |
Strength | 200mg; 100mg; 25mg; 50mg; 12.5mg |
Market Status | Prescription |
Company | Ivax Sub Teva Pharms; Sun Pharm Inds; Mylan |
5 of 6 | |
---|---|
Drug Name | Clozaril |
PubMed Health | Clozapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | CLOZARIL (clozapine), an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine.The structural formula isCLOZARIL is available in pale yellow tablets of 25mg... |
Active Ingredient | Clozapine |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 25mg |
Market Status | Prescription |
Company | Novartis |
6 of 6 | |
---|---|
Drug Name | Fazaclo odt |
Active Ingredient | Clozapine |
Dosage Form | Tablet, orally disintegrating |
Route | Oral |
Strength | 200mg; 100mg; 25mg; 150mg; 12.5mg |
Market Status | Prescription |
Company | Jazz Pharms Iii |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
19
PharmaCompass offers a list of Clozapine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Clozapine manufacturer or Clozapine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Clozapine manufacturer or Clozapine supplier.
PharmaCompass also assists you with knowing the Clozapine API Price utilized in the formulation of products. Clozapine API Price is not always fixed or binding as the Clozapine Price is obtained through a variety of data sources. The Clozapine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lapenax manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lapenax, including repackagers and relabelers. The FDA regulates Lapenax manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lapenax API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lapenax manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lapenax supplier is an individual or a company that provides Lapenax active pharmaceutical ingredient (API) or Lapenax finished formulations upon request. The Lapenax suppliers may include Lapenax API manufacturers, exporters, distributors and traders.
click here to find a list of Lapenax suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lapenax DMF (Drug Master File) is a document detailing the whole manufacturing process of Lapenax active pharmaceutical ingredient (API) in detail. Different forms of Lapenax DMFs exist exist since differing nations have different regulations, such as Lapenax USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lapenax DMF submitted to regulatory agencies in the US is known as a USDMF. Lapenax USDMF includes data on Lapenax's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lapenax USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lapenax suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lapenax Drug Master File in Japan (Lapenax JDMF) empowers Lapenax API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lapenax JDMF during the approval evaluation for pharmaceutical products. At the time of Lapenax JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lapenax suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lapenax Drug Master File in Korea (Lapenax KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lapenax. The MFDS reviews the Lapenax KDMF as part of the drug registration process and uses the information provided in the Lapenax KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lapenax KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lapenax API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lapenax suppliers with KDMF on PharmaCompass.
A Lapenax CEP of the European Pharmacopoeia monograph is often referred to as a Lapenax Certificate of Suitability (COS). The purpose of a Lapenax CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lapenax EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lapenax to their clients by showing that a Lapenax CEP has been issued for it. The manufacturer submits a Lapenax CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lapenax CEP holder for the record. Additionally, the data presented in the Lapenax CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lapenax DMF.
A Lapenax CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lapenax CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Lapenax suppliers with CEP (COS) on PharmaCompass.
A Lapenax written confirmation (Lapenax WC) is an official document issued by a regulatory agency to a Lapenax manufacturer, verifying that the manufacturing facility of a Lapenax active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lapenax APIs or Lapenax finished pharmaceutical products to another nation, regulatory agencies frequently require a Lapenax WC (written confirmation) as part of the regulatory process.
click here to find a list of Lapenax suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lapenax as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lapenax API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lapenax as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lapenax and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lapenax NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lapenax suppliers with NDC on PharmaCompass.
Lapenax Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lapenax GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lapenax GMP manufacturer or Lapenax GMP API supplier for your needs.
A Lapenax CoA (Certificate of Analysis) is a formal document that attests to Lapenax's compliance with Lapenax specifications and serves as a tool for batch-level quality control.
Lapenax CoA mostly includes findings from lab analyses of a specific batch. For each Lapenax CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lapenax may be tested according to a variety of international standards, such as European Pharmacopoeia (Lapenax EP), Lapenax JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lapenax USP).